Need professional-grade analysis? Visit stockanalysis.com
$2.01B
N/A
198
N/A
Celldex Therapeutics Inc (CLDX) trades on United States in USD. The company is classified in the Healthcare sector under the Biotechnology industry. The stock currently trades at $34.25, down 0.87% from the previous close.
Over the past year, CLDX has traded between a low of $18.33 and a high of $34.55. The stock has gained 76.3% over this period. It is currently 86.9% above its 52-week low.
Celldex Therapeutics Inc has a market capitalization of $2.01B.
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases. The company's drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. It develops clinical programs, including Barzolvolimab (CDX-0159), a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity for treating chronic urticarias, prurigo nodularis, eosinophilic esophagitis, and atopic dermatitis; and CDX-622, a bispecific candidate for inflammatory diseases, which targets two complementary pathways that drive chronic inflammation, potently neutralizing the alarmin thymic stromal lymphopoietin and depleting mast cells through stem cell factor starvation. Celldex Therapeutics, Inc. is headquartered in Hampton, New Jersey.
Side-by-side comparison against top Healthcare peers.